

Revised August 2026

Policy for the Control of Transmissible Spongiform Encephalopathy (TSE), Including Creutzfeldt Jakob Disease (CJD) and variant Creutzfeldt Jakob Disease (vCJD)

Nursing, Midwifery & AHPs Directorate

To be used in conjunction with the Guidance issued by The Advisory Committee on Dangerous Pathogens TSE Risk Management Sub-Group:
<https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

Title:	Policy for the Control of Transmissible Spongiform Encephalopathy (TSE), Including Creutzfeldt Jakob Disease (CJD) and variant Creutzfeldt Jakob Disease (vCJD)		
Author(s):	Reviewed and updated by Wendy Cross, Infection Prevention & Control		
Ownership:	Clare McLaughlin, Head of Infection Prevention & Control		
Approval By:	CMT HCAI Accountability Forum Trust Policy Group	Approval Date:	27 May 2026 04 August 2026
Original Operational Date:	November 2010		
Revised Date(s):	November 2011 March 2014 August 2016 August 2020 August 2026	Next Review:	August 2029
Version No.	6.0	Supersedes:	Policy for the Control of Transmissible Spongiform Encephalopathy (TSE) (Including CJD/ vCJD) (August 2020)
Reference Number:	COR/NMAH/009/V6		
Links to Other Policies, Procedures, Guidelines or Protocols:	- To be used in conjunction with the TSE Working Group Guidance ‘Transmissible Spongiform Encephalopathy agents: safe working and the prevention of infection’, which may be accessed via https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group - BSG Guidelines for Decontamination of Equipment for Gastrointestinal Endoscopy (2014) – last updated 10th August 2017 - Disinfection and Decontamination Policy (Patient Care Equipment) - Guidelines on the Collection of Clinical Specimens for Laboratory Examination - Personal Protective Equipment (PPE) Advice for Health and Social Care Staff Infection Prevention & Control Standard Precautions in NI Regional IP&C Manual		

Key Changes from 2020 Version:

- Updated arrangements for Creutzfeldt-Jakob Disease (CJD) in the UK. This reflects the changes following the creation of the National CJD Diagnostic Advisory Service (NCJDAS) based in the University of Edinburgh and reorganising of surveillance services across the UK. This is included as Appendix 7.
- Updated laboratory containment and control measures – [Laboratory containment and control measures \(updated November 2021\)](#).
- Policy reflects the necessary changes regarding the new electronic patient records system, Encompass.

CONTENTS

This policy does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/ or guardian or carer.

SECTION		PAGE
1.0	INTRODUCTION	6
	1.1 Background	6
	1.2 Purpose	7
2.0	SCOPE OF THE POLICY	7
3.0	ROLES AND RESPONSIBILITIES	7
	3.1 Trust Board and Chief Executive	7
	3.2 Senior Managers	7
	3.3 Ward Managers	7
	3.4 All Healthcare Employees within the WHSCT	8
	3.5 Infection Prevention & Control Team	8
	3.6 Consultant Microbiologist	8
	3.7 Clinician Responsible for the Patient	8
4.0	KEY PRINCIPLES	8
5.0	MODE OF TRANSMISSION	8
6.0	PATIENT RISK GROUPS	10
7.0	PRE-ANAESTHETIC ASSESSMENT QUESTIONS	12
8.0	ADDITIONAL RECOMMENDATIONS FOR SURGERY AND NEURO-ENDOSCOPY WHICH MAY/ WILL INVOLVE CONTACT WITH HIGH RISK TISSUES ONLY	14
9.0	ADDITIONAL ACTIONS TO BE TAKEN DURING PRE-SURGERY ASSESSMENT FOR CJD RISK	18
10.0	MANAGING vCJD RISK IN GENERAL SURGERY AND LIVER TRANSPLANTATION	18
11.0	SINGLE-USE INSTRUMENTS	18
12.0	PROBLEMS WITH SURGICAL INSTRUMENTS	18
13.0	SUMMARY OF PRECAUTIONS ADVISED FOR THE USE OF ENDOSCOPES	19
14.0	COMMON FLEXIBLE ENDOSCOPIC PROCEDURES CLASSIFICATION – INVASIVE OR NON-INVASIVE	22
15.0	DECONTAMINATION OF ENDOSCOPES	22
16.0	QUARANTINING OF SURGICAL INSTRUMENTS	22
17.0	MANAGING CJD/ vCJD RISK IN OPHTHALMOLOGY AND CJD GUIDANCE FOR OPHTHALMOLOGISTS	22
18.0	HOSPITAL CARE OF CJD/ vCJD PATIENTS • Sample taking and other invasive medical procedures • Spillages • Clinical Waste • Childbirth • Bed linen • Occupational exposure	22

	• Surgical procedures and instrument management	
19.0	GENERAL PRINCIPLES OF DECONTAMINATION AND WASTE DISPOSAL	23
20.0	DECONTAMINATION OF INSTRUMENTS	23
21.0	INCINERATION OF INSTRUMENTS	23
22.0	TRANSRECTAL PROSTATIC BIOPSY IN MEN AT RISK OF vCJD	23
23.0	COMMUNITY HEALTHCARE OF CJD/ vCJD PATIENTS	23
24.0	TRANSPORTATION OF TSE INFECTED MATERIAL	24
25.0	DENTISTRY	24
26.0	HANDLING OF TISSUES FROM PATIENTS 'WITH', OR 'AT RISK' OF CJD/ vCJD – FOR PATHOLOGISTS AND PATHOLOGY LABORATORIES	24
27.0	AFTER DEATH	24
28.0	SURVEILLANCE: NATIONAL REFERRAL OF SUSPECTED CASES OF CJD	24
29.0	REPORTING NEW CJD CASES TO PUBLIC HEALTH TEAMS	24
30.0	PROTOCOL FOR SURVEILLANCE OF CJD	24
31.0	FREQUENTLY ASKED QUESTIONS – CLINICAL STAFF	25
32.0	IMPLEMENTATION	25
	32.1 Dissemination	25
	32.2 Exceptions	25
33.0	MONITORING	25
34.0	REFERENCES	25
35.0	CONSULTATION PROCESS	26
36.0	EQUALITY STATEMENT	26
37.0	APPENDICES	26
38.0	SIGNATORIES	27
Appendix 1	Handling of Instruments: Patients With or 'At Increased Risk' of CJD (Other than vCJD)	28
Appendix 2	Handling of Instruments: Patients With or 'At Increased Risk' of vCJD	29
Appendix 3	CJD/ vCJD Risk Questionnaire	30
Appendix 4	CJD/ vCJD Endoscope Identification Form	31
Appendix 5	Information for Patients Undergoing Surgery or Neuro-Endoscopy on High Risk Tissues	32
Appendix 6	Algorithm Chart for Precautions for Reusable Instruments for Surgical Procedures on Patients With or 'At Increased Risk' of CJD, vCJD and Other Human Prion Diseases	34
Appendix 7	CMOs Letter: Diagnostics Services and Reporting of CJD Cases and Suspect Cases: Arrangements for 2025-2026	35

1.0 **INTRODUCTION**

The purpose of this policy is to provide all clinical staff with guidance and advice on safe working practices with the aim of preventing the transmission of Creutzfeldt Jakob Disease (CJD), variant Creutzfeldt Jakob Disease (vCJD) and other human prion diseases in hospital and community healthcare settings.

N.B. This document is intended for use by all clinical staff.

All staff must comply with the current policy. Failure to do so may result in disciplinary action.

1.1 **Background**

CJD is a rare illness and is one of a group of diseases called prion diseases, which affect humans and animals. Prion diseases exist in different forms, all of which are progressive, currently untreatable and ultimately fatal. Their name arises because they are associated with an alteration in a naturally occurring protein: the prion protein.

CJD was first described in 1920. The commonest form is called sporadic CJD and occurs worldwide causing around 1-2 deaths per million population per year. A new form of CJD (variant CJD) linked to bovine spongiform encephalopathy (BSE) in cattle was identified in 1996. There are also inherited forms of human prion disease linked to mutations of the prion protein gene and cases caused by infection via medical or surgical treatments (iatrogenic CJD).

This guidance provides advice on safe working practices with the aim of preventing the transmission of CJD, variant CJD (vCJD) and other human prion diseases in hospital and community healthcare settings.

N.B: It is acknowledged some procedures involving 'high risk tissue', e.g. neurosurgery, are not presently performed within the Western Health & Social Care Trust (WHSCT). However, some patients who reside within the WHSCT will have to have such procedures performed at another hospital. Therefore, it is recommended, if possible, that an assessment regarding CJD/ vCJD risk be carried out on such patients prior to them being transferred. If the patient is found to be at risk, then the Infection Prevention & Control (IP&C) Department at the receiving hospital should be informed immediately via telephone.

The responsibility for care and investigation of individual patients remains with the consultant responsible for that patient in consultation with the general practitioner (GP). There will be continuing support for clinicians and pathologists dealing with suspected cases of CJD and related prion diseases available in the National Prion Clinic (NPC) in London and the NCJDAS based in the University of Edinburgh.

Details of the services available are available on the websites and in

Appendix 7:

NCJDAS: <https://cjd.ed.ac.uk/>

NPC: <https://www.uclh.nhs.uk/our-services/find-service/neurology-and-neurosurgery/national-prion-clinic>

1.2 Purpose

This policy aims to provide guidance for all healthcare workers on the safe and effective management of patients with CJD, thereby reducing the risk of transmission to other patients and staff within a healthcare setting by identifying staff roles and responsibilities and providing clear procedures to follow.

2.0 SCOPE OF THE POLICY

This policy applies to all healthcare workers employed within the WHSCT and others working within the Trust in a contracted capacity.

3.0 ROLES AND RESPONSIBILITIES

3.1 Trust Board and Chief Executive

Have an overall governance role in infection prevention and control in relation to staff, patients and visitors. They have a collective responsibility to ensure that patients with suspected/ confirmed CJD/ vCJD can be managed according to the procedures set out in this policy.

3.2 Senior Managers

Within directorates should:

- Ensure staff have access to this policy and adhere to the procedures set out in this policy.
- Have a key role in the co-ordination of actions required.
- Ensure records of meetings are maintained.
- Ensure relevant specialties must carry out audits relating to the compliance with CJD/ vCJD risk assessments. Date(s) and score(s) of same to be kept within the relevant speciality.

3.3 Ward Managers

Ensure that:

- Staff within their area of responsibility adhere to the procedures outlined in this policy.
- Adverse incidents are reported and managed as per Trust policy.
- Staff are provided with suitable information, instruction and training as required.
- Should maintain an accurate record of patient placement within the ward at all times to facilitate accurate retrospective information gathering if required.

- Staff have access to appropriate personal protective equipment (PPE).
- All necessary information requested by an Incident Team is provided as required.
- Ensure necessary documentation has been completed as per policy.

3.4 All Healthcare Employees within the WHSCT

- Must be familiar with this policy.
- Must comply with the WHSCT pre-employment health assessment.

3.5 Infection Prevention & Control Team

- Advise on the infection prevention and control issues for individual patients.
- Contribute to the updating of the Policy for the Control of TSE, Including CJD/ vCJD.

3.6 Consultant Microbiologist

Advise on infection prevention and control issues for individual patients.

3.7 Consultant Responsible for the Patient

Must be familiar with the information set out within this policy. The responsibility for care and investigation of individual patients remains with the consultant responsible for that patient in consultation with the general practitioner. There will be continuing support for clinicians and pathologists dealing with suspected cases of CJD and related prion diseases available in the National Prion Clinic (NPC) in London and the NCJDAS based in the University of Edinburgh.

4.0 KEY PRINCIPLES

The overarching principles/ statements for this policy are to ensure that:

- Staff are informed and instructed in the management and control of CJD/ vCJD.
- The relevant personnel/ departments and agencies are notified of patients suspected or confirmed of prion disease.
- To give advice on completing risk assessments in relation to health and safety of patients and staff.
- To ensure that all procedures for diagnosis, surveillance and treatment are implemented appropriately.
- To ensure that PPE use is appropriate and proportionate.
- To ensure that Trust incidents are investigated appropriately.

5.0 MODE OF TRANSMISSION

- It is important to emphasise that CJD prion diseases are not contagious, but can be transmissible under certain circumstances.

- Normal social and clinical contact and non-invasive procedures **do not** present a risk to healthcare workers (HCWs), visitors, relatives and the community.
- CJD has been transmitted accidentally in human sources, including growth hormones, dura mater preparation and transplantation of a corneal graft donated by an affected patient.
- Infection prevention and control measures, therefore, deal primarily with instruments, tissues and the prevention of inoculation injuries.
- CJD is particularly resistant to standard physical and chemical methods of inactivation and decontamination. **Therefore, effective cleaning is of great importance.**

Table 1 – Distribution of TSE Infectivity in Human Tissues and Body Fluid

Further guidance can be accessed via: Annex A1 at

<https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

Tissue	Presence of abnormal Prion Protein and level of infectivity			
	CJD other than vCJD		vCJD	
	PrP ^{TSE} detected	Assumed level of infectivity	PrP ^{TSE} detected	Assumed level of infectivity
Brain	+ve	High P	+ve	High P
Spinal cord	+ve	High P	+ve	High P
Cranial nerves – specifically • Entire optic nerve • Only the intracranial components of the other cranial nerves	+ve	High	+ve	High
Cranial ganglia	+ve	High	+ve	High P
Posterior eye – specifically • Posterior hyaloid face • Retina • Retinal pigment epithelium • Choroid • Subretinal fluid • Optic nerve	+ve	High P	+ve	High
Pituitary gland	+ve	High (?)	+ve	High (?)
Spinal ganglia ¹	+ve	Medium	+ve	Medium P
Olfactory epithelium	+ve	Medium	NT	Medium
Dura mater ²	-ve	Low	+ve	Low
Tonsil	-ve	Low	+ve	Medium P
Lymph nodes and other organised lymphoid tissues containing follicular structures	-ve	Low P	+ve	Medium P

Gut-associated lymphoid tissue	-ve	Low	+ve	Medium
Appendix	-ve	Low	+ve	Medium
Adrenal gland	-ve	Low	+ve	Medium
Spleen	+ve	Low P	+ve	Medium P
Thymus	-ve	Low	+ve	Medium
Anterior eye and cornea	-ve	Low	-ve	Low
Peripheral nerve	+ve	Low	+ve	Low
Skeletal muscle	+ve	Low	+ve	Low
Dental Pulp	-ve	Low	-ve	Low
Gingival Tissue	NT	Low	-ve	Low
Blood and bone marrow	NT	Low	-ve	Low
CSF	-ve	Low P	-ve	Low
Placenta	-ve	Low	-ve	Low
Urine	-ve	Low	-ve	Low
Other tissues	-ve	Low P	+ve	Low

Key: +ve = tested positive -ve = tested negative NT = not tested
P = infectivity proven in experimental transmission studies

¹ Spinal ganglia have a high assumed level of infectivity in the WHO Guidelines. However, unpublished results on the infectivity of spinal ganglia indicate that this tissue is of medium infectivity.

² Dura mater is designated low infectivity as virtually no detectable abnormal prion protein has been found in cases of CJD; **however, as grafts of these tissues are associated with CJD transmission, probably as a result of contamination by brain and because of the lengthy period of implantation in the CNS, procedures conducted on intradural tissues (i.e. brain, spinal cord and intracranial sections of cranial nerves) or procedures in which human dura mater was implanted in a patient prior to 1992 remain high risk.**

6.0 PATIENT RISK GROUPS

Further guidance may be accessed via: 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>. When considering measures to prevent transmission of CJD to patients or staff in the healthcare setting, it is useful to make a distinction between '**symptomatic**' patients, i.e. those who fulfil the diagnostic criteria for definite, probable or possible CJD or vCJD and '**at increased risk**' patients, i.e. those with no clinical symptoms, but who are at increased risk of developing CJD or vCJD, i.e. because of their medical or family history. Table 2 below details the classification of the risk status of symptomatic and asymptomatic patients.

Table 2 – Categorisation of Patients by Risk

Symptomatic patients	Patients who fulfil the diagnostic criteria for definite, probable or possible CJD or vCJD. (For full diagnostic criteria see Annex B at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group). Patients with neurological disease of unknown aetiology who do not fit the criteria for possible CJD or vCJD, but where the diagnosis of CJD is being actively considered.
Patients 'at increased risk' from genetic forms of CJD	Individuals who have or have had two or more blood relatives affected by CJD or other prion disease. Individuals who have a blood relative known to have a genetic mutation indicative of genetic CJD. Individuals who have been shown by specific genetic testing to be at significant risk of developing CJD.
Patients identified as 'at increased risk' of vCJD through receipt of blood from a donor who later developed vCJD	Individuals who have received labile blood components (whole blood, red cells, white cells or platelets) from a donor who later went on to develop vCJD.
Patients identified as 'at increased risk' of CJD/ vCJD through iatrogenic exposures	Recipients of hormone derived from human pituitary glands, e.g. growth hormone, gonadotrophin, are 'at increased risk' of transmission of sporadic CJD. In the UK the use of human-derived gonadotrophin was discontinued in 1973 and use of cadaver-derived human growth hormone was banned in 1985. However use of human-derived products may have continued in other countries after these dates. Individuals who underwent intradural neurosurgical or intradural spinal procedures before August 1992 who have received (or might have received) a graft of human-derived dura mater are 'at increased risk' of transmission of sporadic CJD (unless evidence can be provided that human-derived <i>dura mater</i> was not used). Individuals who have had surgery using instruments that had been used on someone who went on to develop CJD/ vCJD or was 'at increased risk' of CJD/ vCJD. Individuals who have received an organ or tissue from a donor infected with CJD/ vCJD or 'at increased risk' of CJD/ vCJD. Individuals who have been identified as having received blood or blood

	components from 300 or more donors since January 1990. Individuals who have given blood to someone who went on to develop vCJD. Individuals who have received blood from someone who has also given blood to a patient who went on to develop vCJD. Individuals who have been treated with certain implicated UK sourced plasma products between 1990 and 2001.
--	---

N.B: Recipients of ocular transplants, including corneal transplants, are not considered to be 'at increased risk' of CJD/ vCJD.

7.0 PRE-ANAESTHETIC ASSESSMENT QUESTIONS

Further guidance may be accessed via: Annex J at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group> updated November 2021.

There are a number of patients who have been informed that they are at increased risk of CJD or vCJD. Thus it is now recommended that **all** patients about to undergo **any** elective or emergency surgical or endoscopic procedure are to be asked the following question (with the exception of obstetrics and gynaecological procedures, also refer to section entitled Dentistry) to allow appropriate infection control procedures to be followed.

The CJD/ vCJD Questionnaire(s) **must** be completed at the earliest opportunity by the patient's **clinician** and then filed in the patients medical notes for future reference.

It is crucial that the question(s) are asked in a manner that does not cause undue anxiety, and therefore the questioner should be prepared and able to reassure the patient, and provide further information if needed.

Question: 'Have you ever been notified that you are at increased risk of CJD/ vCJD for public health purposes?' (See Appendix 3).

Table 3 – The actions to be taken following the patient's response to the above questions are

Patient Response	Action
No	Surgery or endoscopy should proceed using normal infection prevention and control procedures, unless the procedure is likely to lead to contact with high risk tissue then additional questions must be asked. (See additional questions page 14, Table 4 and Appendix 3).

Yes	• Please ask them to explain further. • If a patient has answered ‘yes’, there is no additional need to ask the questions in Table 4/ Appendix 3, as the patient’s risk status has been established. • Special infection prevention and control precautions should be taken for all surgery or endoscopy involving contact with <u>medium</u> or <u>high</u> infectivity tissues. The Infection Prevention & Control Team should be consulted for advice. • Advice on the precautions to be taken during the treatment of patients with or at increased risk of CJD/ vCJD can be accessed via ‘Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings’ Part 4 at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group • Annex F at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group provides information on endoscopic procedures. • The patient’s response must be recorded in their electronic care record CJD risk assessment. • Record CJD in ‘Infection Status’ in the patient’s electronic care record.
Unable to respond	• Surgery or endoscopy should proceed using normal infection prevention and control procedures unless the procedure is likely to lead to contact with high risk tissue. • In the event that a patient about to undergo emergency surgery or endoscopy is physically or otherwise unable to answer any questions, a family member or someone close to the patient (in the case of a child, a person with parental responsibility) should be asked the CJD risk question and those set out in Table 4, prior to surgery or endoscopy. • If the family member or someone close to the patient is not able to provide a definitive answer to the CJD risk questions, the surgery or neuro-endoscopy should proceed <u>but all instruments should be quarantined following the procedure.</u> • The patient’s GP should be contacted after the surgery or neuro-endoscopy and enquiries made as to whether the patient is at risk of CJD/ vCJD according to the CJD risk questions set out in Table 4.

If a patient answers **no** to the above question, but is already **known** to be at risk and is undergoing **any** elective or emergency surgical or endoscopic procedures likely to involve contact with tissues of potentially **medium/ high** level infectivity, refer to ‘Summary of Precautions Advised for the Use of Endoscopes’ pages 19-21. Also ‘Handling of Instruments’ – Appendix 1 and 2 of this policy.

8.0 **ADDITIONAL RECOMMENDATIONS FOR SURGERY AND NEURO-ENDOSCOPY WHICH MAY/ WILL INVOLVE CONTACT WITH HIGH RISK TISSUE ONLY**

As well as asking **all** patients whether they have been notified as being at risk of CJD/ vCJD clinicians assessing patients who are coming in for procedures that are likely to/ will involve contact with **high risk** tissues **must** ask the following supplementary questions to further assess CJD/ vCJD risk. These questions are included in the Questionnaire, Appendix 3.

N.B: It is recommended that patients are asked the questions outlined in Table 4 prior to elective or emergency surgical or neuro-endoscopic procedures likely to involve contact with tissues of potentially **high** infectivity.

Procedures should **not** be delayed whilst information is being collected and clinicians should be careful not to prejudice overall patient care.

Table 4

	Questions to Patient	Notes to Clinician
1	Have you any history of CJD or other prion disease in your family? If yes, please specify/ comment on electronic care record/ CJD risk assessment.	Patient should be considered to be at risk from genetic forms of CJD if they have or have had: i) Genetic testing, which has indicated that they are at significant risk of developing CJD or other prion disease; ii) A blood relative known to have a genetic mutation indicative of genetic CJD or other prion disease; iii) 2 or more blood relatives affected by CJD or other prion disease.
2	Have you ever received growth hormone or gonadotrophin treatment? If yes, please specify/ comment on electronic care record: i) whether the hormone was derived from human pituitary glands? ii) the year of treatment iii) whether the treatment was received in the UK or in another country	Recipients of hormone derived from human pituitary glands, e.g. growth hormone or gonadotrophin, have been identified as potentially at risk of sporadic CJD. In the UK, the use of human derived growth hormone was discontinued in <u>1985</u> but human-derived products may have continued to be used in other countries. In the UK, the use of human-derived gonadotrophin was discontinued in <u>1973</u> but may have continued in other countries after this time.

3	Have you had surgery on your brain or spinal cord?	a) Individuals who underwent intradural brain or intradural spinal procedures before August 1992 who have received (or may have received) a graft of human-derived <i>dura mater</i>, are 'at increased risk' of transmission of sporadic CJD (unless evidence can be provided that human-derived <i>dura mater</i> was not used). Patients who received a graft of human-derived <i>dura mater</i> before 1992 are at increased risk of transmission of sporadic CJD, but not vCJD. b) <u>NICE guidance</u> emphasises the need for a separate pool of new neuroendoscopes and reusable surgical instruments for high risk procedures on children born since 1st January 1997 and who have not previously undergone high risk procedures. These instruments should not be used for patients born before 1st January 1997 or those who underwent high risk procedures using reusable instruments before the implementation of this guidance.
----------	--	--

The actions to be taken following the patients response to the questions in Table 4 are:

Patients Response	Action
No to all questions	Surgery or neuro-endoscopy can proceed using normal infection prevention and control procedures.
Yes to any of the questions 1, 2 or 3	Further investigations into the nature to the patient's CJD risk should be undertaken and the patient's CJD risk assessed. This assessment of CJD risk should be recorded in the patient's medical notes for future reference. If the patient is found to be at risk of CJD or vCJD following investigation or the risk status is unknown at the time of the procedure, special infection prevention and control precautions should be taken for the patient's procedure, including quarantining of instruments, and the Infection Prevention & Control Team should be consulted for advice.

	• Advice on the precautions to be taken during the treatment of patients with or at increased risk of CJD/ vCJD can be accessed via 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group • Annex F at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group provides information on endoscopic procedures. Record in the patient's electronic care record CJD risk assessment. If the patient is found to be at increased risk of CJD or vCJD they should be referred to their GP, who will need to inform them that they are at risk of CJD or vCJD and provide them with further information and advice. The responsibility for care and investigation of individual patients remains with the consultant responsible for that patient in consultation with the general practitioner. There will be continuing support for clinicians and pathologists dealing with suspected cases of CJD and related prion diseases available in the National Prion Clinic (NPC) in London and the NCJDAS based in the University of Edinburgh. Details of the services available are available on the websites: NCJDAS: https://cjd.ed.ac.uk/ NPC: https://www.uclh.nhs.uk/our-services/find-service/neurology-and-neurosurgery/national-prion-clinic Refer to Appendix 7.
Unable to respond	In the event that a patient about to undergo emergency surgery or neuro-endoscopy is physically or otherwise unable to answer any questions, a family member or someone close to the patient (in the case of a child, a person with parental responsibility) should be asked the CJD risk questions as set out in Table 4. If the family member or someone close to the patient is not able to provide a definitive answer to the CJD risk questions, the surgery or neuro-endoscopy should proceed <u>but all instruments should be quarantined following the procedure</u>. See Annex E at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group for details on quarantining.

	The patient's GP should be contacted after the surgery or neuro-endoscopy and enquiries made as to whether the patient is at risk of CJD/ vCJD according to the CJD risk questions as set out in Table 4.
--	---

The actions to be taken following the GP's response to the questions in Table 4 are:

GP's Response	Action
No to all questions	The instruments can be returned to routine use after undergoing normal decontamination processes.
Yes to any of questions 1, 2 or 3	Further investigation into the nature to the patients CJD risk should be undertaken by medical staff, and the patient's CJD risk confirmed or rejected. Confirmation or rejection of CJD risk must be recorded in the patient's medical notes for future reference. Record in the patient's electronic care record CJD risk assessment and record CJD in 'Infection Status'. If the patient is found to be at risk of CJD or vCJD following investigation then the quarantined instruments should be <u>destroyed</u>. Alternatively, instruments destined for disposal may instead be retained for research, refer to Annex E at https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group The patient's GP should inform the patient that they are at risk of CJD or vCJD and provide them with further information and advice. The responsibility for care and investigation of individual patients remains with the consultant responsible for that patient in consultation with the general practitioner. There will be continuing support for clinicians and pathologists dealing with suspected cases of CJD and related prion diseases available in the National Prion Clinic (NPC) in London and the NCJDAS based in the University of Edinburgh. Details of the services available are available on the websites: NCJDAS: https://cjd.ed.ac.uk/ NPC: https://www.uclh.nhs.uk/our-services/find-service/neurology-and-neurosurgery/national-prion-clinic Refer to Appendix 7.

Uncertain about any of the questions 1, 2 or 3	The instruments should be kept in quarantine. The Infection Prevention & Control Team will carry out a risk assessment. The outcome of the risk assessment will determine whether or not to return the instrument to routine use.
--	---

9.0 **ADDITIONAL ACTIONS TO BE TAKEN DURING PRE-SURGERY ASSESSMENT FOR CJD RISK**

In addition to asking the patient CJD/ vCJD risk questions, the following actions should also be carried out before any surgical or endoscopic procedure involving contact with **high risk** tissue. The clinician undertaking the pre-surgery assessment should:

- Check the patient's medical notes and/ or referral letter for any mention of CJD/ vCJD status.
- Consider whether there is a risk that the patient may be showing the early signs of CJD or vCJD, i.e. consider whether the patient may have an undiagnosed neurological disease involving cognitive impairment or ataxia.

These actions, in conjunction with the CJD/ vCJD risk questions, will minimise the chance of a CJD incident occurring and therefore greatly reduce the risk of transmission of CJD/ vCJD to subsequent patients.

10.0 **MANAGING vCJD RISK IN GENERAL SURGERY AND LIVER TRANSPLANTATION**

Further guidance can be accessed via Annex M at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

11.0 **SINGLE-USE INSTRUMENTS**

The quality and performance of single-use instruments should be equivalent to those of reusable instruments with appropriate procurement, quality control and audit mechanisms in place. This should include assessment of residual post-production organic contamination.

12.0 **PROBLEMS WITH SURGICAL INSTRUMENTS**

If any problems are identified with instruments or sets of instruments, this should be referred to MHRA through the Yellow Card Scheme. (<https://yellowcard.mhra.gov.uk/>).

13.0 **SUMMARY OF PRECAUTIONS ADVISED FOR THE USE OF ENDOSCOPES**

Further guidance can be accessed via Annex F at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

Table 1 - CJD other than vCJD

Tissue Infectivity	Status of Patient		
	Symptomatic		Asymptomatic
	Definite/ Probable	Possible/ Diagnosis Unclear ¹	At Risk ² inherited/ iatrogenic
High: - Brain - Spinal Cord	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on the same index patient	Single use OR Quarantine pending diagnosis	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient
Medium: Olfactory Epithelium*	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on the same index patient	Single use OR Quarantine pending diagnosis	Single use ⁴ OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient
Low/ None Detectable: All other tissue	No special precautions ⁴	No special precautions ⁴	No special precautions ⁴

Table 2 - vCJD and CJD type uncertain

Tissue Infectivity	Status of Patient			
	Symptomatic		Asymptomatic	
	Definite/ probable	Possible vCJD, possible sCJD or	At risk (blood*** recipient from a donor who	At risk ² Other iatrogenic

		diagnosis unclear¹	later developed vCJD)	
High: - Brain - Spinal cord	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient	Single use OR Quarantine pending diagnosis	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same patient	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same patient
Medium: Olfactory epithelium*	Single use OR Remove from use OR Quarantine ³ for re-use exclusively on same index patient	Single use OR Quarantine pending diagnosis	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient	No special precautions unless contaminated with olfactory epithelium*. If contaminated: single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient
Medium: Lymphoid tissue**	Single use OR Remove from use OR Quarantine ³ for re-use exclusively on same index patient	Single use OR Quarantine pending diagnosis	Single use OR Destroy after use OR Quarantine ³ for re-use exclusively on same index patient	No special precautions ⁴
Low/ none detectable: All other tissues	No special precautions ⁴	No special precautions ⁴	No special precautions ⁴	No special precautions ⁴

* The advice of the consultant carrying out the endoscopic procedure in the nasal cavity should be sought to determine whether a risk of contamination of the endoscope with olfactory epithelium can be excluded with confidence. If

such contamination **cannot** be excluded, take precautions appropriate for **medium** infectivity tissues.

** Lymphoid tissue refers to the spleen, thymus, tonsils and adenoids, lymph nodes, the appendix and the gastro-intestinal tract sub-mucosa. Further guidance re Transrectal Prostatic Biopsy in Men at Risk of vCJD can be accessed via: <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

*** A small number of individuals are known to have received labile blood components (whole blood, red cells, white cells or platelets) from a donor who later developed vCJD.

¹ This includes patients with neurological disease of unknown aetiology who do not fit the criteria for possible CJD but where a diagnosis of CJD is being actively considered. Also see Annex B at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

² This advice refers to the use of flexible endoscopes in patients at risk of developing CJD. For guidance on the use of rigid endoscopes that can be autoclaved, refer to the guidance for the use of all surgical instruments in at risk patients. See 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

³ Quarantined endoscopes may be re-used exclusively on the same individual patient if required. The principles behind the procedures recommended for quarantining of surgical instruments in Annex E at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>, should be followed **except** for endoscopes, the bedside clean should take place immediately after the procedure has been carried out and it is recommended that the endoscopes should be manually cleaned according to the manufacturer's recommendations and passed through an Endoscope Washer Disinfector as soon as possible after use, **before** being quarantined. The endoscope should be decontaminated alone using an Automatic Endoscope Washer Disinfector (EWD). The EWD should be decontaminated as per paragraph F1 (e), Annex F at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

⁴ The decontamination procedures advised in paragraph F1, Annex F at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group> taken together with the **CFPP 01-06** or equivalent national guidance and **BSG Guidelines for Decontamination of Equipment for Gastrointestinal Endoscopy (2014)** should be followed.

14.0 COMMON FLEXIBLE ENDOSCOPIC PROCEDURES CLASSIFICATION – INVASIVE OR NON-INVASIVE

Further guidance can be accessed via Annex F, Table F 2b (Table F 2b refers only to vCJD) at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>.

15.0 DECONTAMINATION OF ENDOSCOPES

Further guidance can be accessed via: Annex F and E at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

16.0 QUARANTINING OF SURGICAL INSTRUMENTS

Further guidance can be accessed via Annex F and E at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

17.0 MANAGING CJD/ vCJD RISK IN OPHTHALMOLOGY AND CJD GUIDANCE FOR OPHTHALMOLOGISTS

Further guidance can be accessed via Annex L at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

18.0 HOSPITAL CARE OF CJD/ vCJD PATIENTS

- **Sample taking and other invasive medical procedures**
- **Spillages**
- **Clinical waste**
- **Child birth**
- **Bed linen**
- **Occupational exposure**
- **Surgical procedures and instrument management**

Further guidance can be accessed via 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

19.0 GENERAL PRINCIPLES OF DECONTAMINATION AND WASTE DISPOSAL

Further guidance can be accessed via Annex C at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

20.0 DECONTAMINATION OF INSTRUMENTS

Research demonstrates that allowing surgical instruments to dry for more than fifteen minutes before reprocessing greatly increases the amount of residual protein contamination. Therefore, instruments should be transported to the HSDU immediately after the close of the procedure for cleaning and reprocessing as soon as practically possible. This will make the cleaning process more effective, hence reducing the risks to the patients and staff handling the devices. If devices cannot be returned in a timely manner, it is important that the instruments are kept moist using appropriate methods approved and verified by the HSDU.

Further guidance can be accessed via Annex C at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

21.0 INCINERATION OF INSTRUMENTS

Further guidance can be accessed via 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

22.0 TRANSRECTAL PROSTATIC BIOPSY IN MEN AT RISK OF vCJD

Further guidance can be accessed via <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

23.0 COMMUNITY HEALTHCARE OF CJD/ vCJD PATIENTS

Further guidance can be accessed via 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

24.0 TRANSPORTATION OF TSE INFECTED MATERIAL

Further guidance can be accessed via Annex D at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

25.0 DENTISTRY

If a patient informs a dentist that they have CJD / vCJD or have been notified that they are 'at risk' of CJD, then the dentist **must** include this in the patient's dental records and any referral for surgery.

Further guidance can be accessed via 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

26.0 HANDLING OF TISSUES FROM PATIENTS 'WITH' OR 'AT RISK OF' CJD OR vCJD – FOR PATHOLOGISTS AND PATHOLOGY LABORATORIES

Further guidance can be accessed via Annex K at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

27.0 AFTER DEATH

Further guidance can be accessed via Annex H at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

28.0 SURVEILLANCE: NATIONAL REFERRAL OF SUSPECTED CASES OF CJD

Refer to Appendix 7.

29.0 REPORTING NEW CJD CASES TO PUBLIC HEALTH TEAMS

Refer to Appendix 7.

30.0 PROTOCOL FOR SURVEILLANCE OF CJD

Refer to Appendix 7.

31.0 FREQUENTLY ASKED QUESTIONS – CLINICAL STAFF

Further guidance can be accessed at

<https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

32.0 IMPLEMENTATION

32.1 Dissemination

This policy applies to all staff.

The policy shall be available for staff to access on the Trust Intranet.

Staff shall be alerted via Trust Communication in relation to the availability of the policy on the Trust Intranet.

32.2 Exceptions

There are no exceptions.

33.0 MONITORING

Compliance with this policy shall be monitored by the Ward/ Department Manager, Team Leader/ Lead Nurse/ Head of Service. The Infection Prevention & Control Team may also independently monitor compliance.

34.0 REFERENCES

Department of Health: Transmissible Spongiform Encephalopathy Agents; Safe Working and the Prevention of Infection. Guidance from the Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee. London: The Stationery Office. www.dh.gov.uk

The National CJD Research & Surveillance Unit (NCJDRSU). The University of Edinburgh. www.cjd.ed.ac.uk

Gateway Approval Reference Number: 8100 Department of Health April 2007. Chief Dental Officer for England.

National Institute for Health and Clinical Excellence: Patient safety and the reduction of risk of transmission of Creutzfeldt-Jakob Disease (CJD) via interventional procedures. Issue date November 2006. <http://www.nice.org.uk>

The Advisory Committee on Dangerous Pathogens' TSE Risk Managements Sub-Group:
<https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>

35.0 CONSULTATION PROCESS

Infection Prevention & Control Team
Consultant Microbiologists
Lead BMS, Haematology & Blood Transfusion
Decontamination Manager
Medical Director
Staff Side Consultation Group
CMT HCAI Accountability Forum
Nursing, Midwifery & AHPs Directorate Senior Management Team
Corporate Management Team
Trust Board

36.0 EQUALITY STATEMENT

In line with duties under the equality legislation (Section 75 of the Northern Ireland Act 1988), Targeting Social Need Initiative, Disability Discrimination and the Human Rights Act 1998, an initial screening exercise to ascertain if this policy should be subject to a full impact assessment has been carried out. The outcome of the equality screening for this policy is:

Major Impact ☐

Minor Impact ☐

No Impact ☒

37.0 APPENDICES

Appendices to this policy are as follows:

- Appendix 1 – Handling of Instruments: Patients With or ‘At Increased Risk’ of CJD (Other than vCJD)
- Appendix 2 – Handling of Instruments: Patients With or ‘At Increased Risk’ of vCJD
- Appendix 3 – CJD/ vCJD Risk Questionnaire
- Appendix 4 – CJD/ vCJD Endoscope Identification Form
- Appendix 5 – Information for Patients Undergoing Surgery or Neuro-Endoscopy on High Risk Tissues
- Appendix 6 – Algorithm Chart for Precautions for Reusable Instruments for Surgical Procedures on Patients With or ‘At Increased Risk’ of CJD, vCJD and Other Human Prion Diseases
- Appendix 7 – CMOs Letter: Diagnostic Services and Reporting CJD Cases and Suspect Cases Arrangements for 2025-2026

38.0 **SIGNATORIES**

Signed for and on behalf of the Western Health and Social Care Trust:

Wendy Cross
Wendy Cross
Infection Prevention & Control

02/09/26
Date

Clare McLaughlin
Clare McLaughlin
Head of Infection Prevention & Control

4/9/26
Date

Appendix 1 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>. 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4.

HANDLING OF INSTRUMENTS: PATIENTS WITH OR 'AT INCREASED RISK' OF CJD (OTHER THAN vCJD)

Tissue Infectivity	Status of Patient		
	Definite or Probable	Possible	At Increased Risk
High* Brain Spinal cord Cranial nerves, specifically the entire optic nerve and the intracranial components of the other cranial nerves Cranial ganglia Posterior eye, specifically the posterior hyaloids face, retina, retinal pigment epithelium, choroid, subretinal fluid and optic nerve Pituitary gland	Single use or Destroy or Quarantine for re-use exclusively on the same patient	Single use or Quarantine for re-use exclusively on the same patient pending diagnosis	Single use or Destroy or Quarantine for re-use exclusively on the same patient
Medium Spinal ganglia Olfactory epithelium	Single use or Destroy or Quarantine for re-use exclusively on the same patient	Single use or Quarantine for re-use exclusively on the same patient pending diagnosis	Single use or Destroy or Quarantine for re-use exclusively on the same patient
Low	No special precautions	No special precautions	No special precautions

Appendix 2 at <https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group>. 'Infection Prevention and Control of CJD, vCJD and other human prion diseases in healthcare and community settings', Part 4.

HANDLING OF INSTRUMENTS: PATIENTS WITH OR 'AT INCREASED RISK' OF vCJD

Tissue Infectivity	Status of Patient		
	Definite or Probable	Possible	At Increased Risk
High* Brain Spinal cord Cranial nerves, specifically the entire optic nerve and the intracranial components of the other cranial nerves Cranial ganglia Posterior eye, specifically the posterior hyaloids face, retina, retinal pigment epithelium, choroid, subretinal fluid and optic nerve Pituitary gland	Single use or Destroy or Quarantine for re-use exclusively on the same patient	Single use or Quarantine for re-use exclusively on the same patient pending diagnosis	Single use or Destroy or Quarantine for re-use exclusively on the same patient
Medium Spinal ganglia Olfactory epithelium Tonsil Appendix Spleen Thymus Adrenal gland Lymph nodes and gut-associated lymphoid tissues	Single use or Destroy or Quarantine for re-use exclusively on the same patient	Single use or Quarantine for re-use exclusively on the same patient pending diagnosis	Single use or Destroy or Quarantine for re-use exclusively on the same patient
Low	No special precautions	No special precautions	No special precautions

* Although dura mater is designated low infectivity tissue, procedures conducted on intradural tissues (i.e. brain, spinal cord and intracranial sections of cranial nerves) or procedures in which human dura mater has been implanted in a patient prior to 1992, are high risk and instruments should be handled as such.

Appendix 3

CJD/ vCJD Risk Questionnaire

The CJD/ vCJD Questionnaire/s must be completed at the earliest opportunity by the patient's **clinician** and then filed in the patient's medical notes for future reference.

The Questionnaire must also be completed prior to any patient being transferred to the Day Case Unit/ Endoscopy Unit at another hospital for Endoscopic procedures, e.g. ERCP.

Question A: To be asked to **all** patients about to undergo **any** elective or emergency surgical or endoscopic procedures.

Questions 1, 2 & 3: To be asked to patients about to undergo elective or emergency surgical or endoscopic procedures likely to involve contact with tissues of potentially **high** level infectivity.

N.B. If a patient answers **no** to Question A but is already **known** to be at risk and is undergoing **any** elective or emergency surgical or endoscopic procedures likely to involve contact with tissues of potentially **medium/ high** level infectivity, refer to 'Summary of Precautions Advised for the Use of Endoscopes', pages 19-21. Also 'Handling of Instruments' – Appendix 1 and 2 of this policy. **(Please tick the appropriate box)**

Question to Patient		Yes	No
A	Have you ever been notified that you are at increased risk of CJD or vCJD for public health purposes?		
1	Have you any history of CJD or other prion disease in your family? If yes, please specify.		
2	Have you ever received growth hormone or gonadotrophin treatment? If yes, please specify i) whether the hormone was derived from human pituitary glands? ii) the year of treatment? iii) whether the treatment was received in the UK or in another country?		
3	Have you had surgery on your brain or spinal cord before August 1992?		
Patient H&C/ Hospital Number	Date	Ward/ Dept. & Hospital	Categorisation – CJD/ vCJD
Signature, Title (PRINT) & GMC No.			
Procedure to be performed:			
Outcome of risk assessment:			

Appendix 4

CJD/ vCJD Endoscope Identification Form

To be completed when an endoscope is placed in Quarantine.

Department/ Hospital:

Patient's Name:

Patient's Date of Birth:

H&C/ Hospital Number:

Endoscope ID:

Endoscope Serial Number:

Endoscope Procedure and Date:

.....
.....
.....
.....
.....
.....
.....

Consultant/ Nurse Endoscopist (Print in full):

.....

Adverse Incident Form Complete: Yes / No

Signature

Endoscopy Clinician:

Appendix 5

The following leaflet can be accessed via

<https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group> Annex J, Appendix B.

INFORMATION FOR PATIENTS UNDERGOING SURGERY OR NEURO-ENDOSCOPY ON HIGH RISK TISSUES

Part of your routine assessment before surgery includes some questions to find out whether you could have an increased risk of Creutzfeldt-Jakob disease (CJD). We will ask you:

Have you ever been notified that you are at risk of CJD or vCJD for public health purposes?

Have you any history of CJD or other prion disease in your family?

Have you ever received growth hormone or gonadotrophin treatment?

Have you had surgery on your brain or spinal cord at any time in the past?

What is CJD?

Creutzfeldt-Jakob disease (CJD) is a rare brain disorder that affects about 1 in a million people each year. CJD is thought to be caused by the build up in the brain of an abnormal form of a protein called a 'prion'. Unfortunately CJD is fatal, and as yet there is no known cure. There are different types of CJD, including variant CJD (vCJD). vCJD is caused by eating meat from cows infected with BSE.

How can CJD spread from person to person?

A person who is infected with CJD may have abnormal prion protein in their body for years before becoming ill. If that person has an operation, or donates blood, tissues or organs, during that time, the abnormal prion protein that causes CJD could spread to other patients.

Why are we asking you about CJD before your operation?

The abnormal prion protein that causes CJD is very hard to remove or destroy. If surgical instruments are used on a patient who is infected with CJD they may still have prion protein on them, even after they have been properly washed and disinfected. They could then spread CJD to other patients. This is particularly important for operations on the brain, spinal cord and the back of the eye as these parts of the body contain the largest amount of abnormal prion protein.

What have these questions got to do with CJD?

CJD has been spread in several ways and different groups of people may have an increased risk of CJD.

We ask whether there is anyone in your family who has had CJD because some types of CJD can be inherited. These types of CJD are caused by faulty genes and may be passed from parent to child.

We ask whether you have had surgery on the brain or spinal cord because some of these operations used to use grafts of 'dura mater' (the tough lining round the brain and spinal cord). Some of these grafts have been linked to CJD infection - these grafts are no longer used.

We ask whether you have been treated with growth hormone or gonadotrophin infertile treatment because these used to be prepared from pituitary glands. Some of these hormone treatments have been linked to CJD infection - these hormones are no longer used.

We ask whether you have had a large number of blood transfusions as this could be related to an increased risk of variant CJD (vCJD). vCJD is the type of CJD which is caused by eating meat from cows infected with BSE. vCJD can be spread through blood transfusions.

What happens if I answer 'Yes' to any of these questions?

If you answer 'Yes' to any of these questions, medical staff will now examine your medical records in more detail to determine whether or not you may have an increased risk of CJD.

What will happen then?

If you do have an increased risk of CJD special precautions will be taken with the surgical instruments used in your operation. Your GP will be informed and will ask you to come and discuss what this means in more detail.

Please remember that the overall risk of CJD spreading by these routes is generally **very low**. These questions are an extra measure to prevent CJD spreading through surgery. **This should not affect the medical care you receive now or in the future.**

What if I don't have a GP?

The health protection unit for your area will make sure that another doctor discusses this with you.

Can I have a blood test to see if I am infected with CJD?


Unfortunately there is no blood test available yet which could show if you have CJD.

Where can I find out more?

The following organisations offer further information and support.

- ☐ CJD Support Network website: www.cjdsupport.net
- ☐ National CJD Surveillance Unit website: www.cjd.ed.ac.uk
- ☐ National Prion Clinic website: www.nationalprionclinic.org/

ALGORITHM CHART FOR PRECAUTIONS FOR REUSABLE INSTRUMENTS FOR SURGICAL PROCEDURES ON PATIENTS WITH OR “AT INCREASED RISK” OF CJD, VCJD AND OTHER HUMAN PRION DISEASES



Appendix 7



To: Neurologists/neuropathologists

29th August 2025

Dear Colleague,

DIAGNOSTICS SERVICES AND REPORTING OF CJD CASES AND SUSPECT CASES: ARRANGEMENTS FOR 2025-2026

This letter updates arrangements for Creutzfeldt-Jakob Disease (CJD) in the UK. It updates the 2004 CMO letter and subsequent 2016 public health reporting arrangements letter. This reflects the changes following the creation of the National CJD Diagnostic Advisory Service (NCJDAS) based in the University of Edinburgh and reorganising of surveillance services across the UK.

The UK CMOs remain committed to ensure appropriate diagnosis and surveillance are in place for the purpose of minimising the risk of spread of CJD in the UK population.

The responsibility for care and investigation of individual patients remains with the consultant responsible for that patient in consultation with the general practitioner. There will be continuing support for clinicians and pathologists dealing with suspected cases of CJD and related prion diseases available in the National Prion Clinic (NPC) in London and the NCJDAS based in the University of Edinburgh.

Details of the services available are available on the websites:

- NCJDAS: <https://cjd.ed.ac.uk/>
- NPC: <https://www.uclh.nhs.uk/our-services/find-service/neurology-and-neurosurgery/national-prion-clinic>

Clinicians across the UK can access these services. To access these services:

1. Clinicians are asked to continue to **refer to both the NCJDAS and NPC** using the referral form available on the website <https://cjd.ed.ac.uk/>. The two units will liaise to ensure both are aware of all referrals:
 - NCJDAS: loth.securecjd@nhs.scot,
 - NPC: uclh.prion.help@nhs.net
2. Expert advice on the **clinical diagnosis** of CJD and related prion diseases will be provided by NCJDAS and NPC. Investigations to support a clinical diagnosis will be available, including:
 - CSF RT-QuIC testing via the national CSF RT-QuIC Laboratory, based in Edinburgh. Clinicians are to make requests to this directly, using the CSF request form available on the website (<https://cjd.ed.ac.uk/csf>) and the subsequent results will be shared with the NPC.
 - *PRNP* gene sequencing conducted by the NPC in London
3. An NHS commissioned provision for **specialist nursing care and advice** is available through the integrated services of NPC in London, and/or nurses in NHS Lothian in Edinburgh. Together, these services support patients with suspected or confirmed prion disease and their families across the UK. Access to specialist nursing teams should be initiated after completion of a diagnostic process involving the NPC and NCJDAS, to ensure clarity for patients and their families, appropriate triage and resource allocation.

Clinicians seeking to request care support for CJD patients may contact the services using the following details:

- NCJDAS: loth.specialistncjd@nhs.scot
- NPC: uclh.prion.help@nhs.net

Given the importance of identifying new cases, it is also the responsibility of the clinician, Trust or Health Board to **report suspected cases and deaths**. Please ensure the following are notified:

- Your Health Board or Trust's **infection control team**, who can identify contact details of the local health protection/public health team if necessary
- Your **local health protection or public health team** who will then work with the relevant trusts, hospitals or health boards to investigate and manage any public risk.

The reporting arrangements across the UK are as follows:

	How to report CJD cases for public health and surveillance	Website or contact details
England	All suspected or confirmed cases of CJD should be reported by notification through NOIDS, the Notification of Infectious Diseases.	Link to NOIDS: https://www.gov.uk/guidance/report-a-notifiable-disease
Northern Ireland	All suspected cases of CJD should be reported to the Health Protection Service in PHA by email (without including patient details), requesting a call back. A member of the health protection team will then contact the clinician to collect information.	Email: PHA.DutyRoom@hscni.net Phone: 0300 555 0119
Scotland	All confirmed probable and possible cases of CJD to be reported to the local NHS board Health Protection Team (HPT) in their Public Health Department requesting a call back. A member of the HPT will then contact the clinician to collect information. Confirmed, probable and possible cases will be reported to PHS by Health Protection Teams and by the NCJDAS.	Link to contact details of the Health Protection Teams in Scotland: https://publichealthscotland.scot/contact-us/general-enquiries/health-protection-team-contacts/
Wales	Notify the Public Health Wales Health Protection Team of any possible, probable or confirmed cases of CJD by emailing the Public Health Wales Health Protection Team.	Email: aware@wales.nhs.uk Phone: 0300 00 300 32

Yours sincerely,

Professor Chris Whitty, Chief Medical Officer, England

Professor Isabel Oliver, Chief Medical Officer, Wales

Professor Sir Michael McBride, Chief Medical Officer, Northern Ireland

Professor Sir Gregor Smith, Chief Medical Officer, Scotland